Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies

• Main Authors: April Armstrong (Author), Alvaro González-Cantero (Author), Saakshi Khattri (Author), Guilherme Muzy (Author), William N. Malatestinic (Author), Anastasia Lampropoulou (Author), Meghan Feely (Author), Sophia Kyoungah See (Author), Can Mert (Author), Andrew Blauvelt (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2024-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Introduction The National Psoriasis Foundation (NPF) recommends evaluating patient response to treatment at week 12, with a target response of ≤ 1% body surface area (BSA) affected by plaque psoriasis and an acceptable response of BSA ≤ 3% or ≥ 75% improvement. This post hoc analysis compar...